
Direct-to-consumer genetic or over the counter testing emerged in the early 2000s as a means of allowing consumers to access information about their genetics without the involvement of a physician. While early models were popular with consumers, they were controversial in medical and regulatory circles.
In the January 2018 issue of Mayo Clinic Proceedings authors Megan Allyse Ph.D., David Robinson, Matthew Ferber Ph.D. and Richard Sharp Ph.D. trace the history of direct-to-consumer genetic testing, discuss its regulatory implications, and describe the emergence of a new hybrid model.
Direct-to-consumer testing — the early days
In 2007 the journal Science named human genetic variation the “breakthrough of the year” and direct-to-consumer companies were offering microarray panels for $1,000. Fast forward five years and the curious consumer could get a microarray panel for $99. Microarray refers to a microchip-based testing platform that allows high-volume, automated analysis of many pieces of DNA at once.
“Consumers liked the convenience of direct-to-consumer testing, the appeal of gaining access to their personal genetic information, and its promotion of preventive and individualized medicine,” says Dr. Allyse, a Mayo Clinic bioethicist, and lead-author of the paper. Read the rest of the article on the Mayo Clinic Center for Innovation blog.
_________________________________________________
Other Mayo Clinic medical research websites:
ROCHESTER, Minn. — Heart failure is a potentially urgent health concern for young adults with congenital heart disease (ACHD) that is often overlooked and undertreated, ...
Mayo Clinic doctors are using innovation to improve the lives of people who suffer from congestive heart failure and other chronic heart conditions. The Organ ...
Mayo Clinic researchers studying the genetics of people who had recently developed dilated cardiomyopathy, one of the most common causes of heart failure, have found a ...